Results 121 to 130 of about 133,818 (257)

Pharmacological effects of gastrodin: Insight into neurological diseases and mechanism in ferroptosis and pyroptosis

Ibrain, Volume 11, Issue 1, Page 74-83, Spring 2025.
Pharmacological effects of gastrodin include prevention and treatment of cognitive decline and reperfusion injuries, anticonvulsion, antiepilepsy, antidepressants, and analgesia, which are related to antiferroptosis and antipyroptosis. Abstract Gastrodin, as an effective monomer of gastrodia elata, plays a significant role in anti‐inflammatory ...
Xue Zheng, Jing Li, Zhao‐Qiong Zhu
wiley   +1 more source

Somatic cell reprogramming for Parkinson's disease treatment

Ibrain, Volume 11, Issue 1, Page 59-73, Spring 2025.
The fundamental purpose of cell reprogramming to treat Parkinson's disease is to generate dopaminergic neurons (DAN) and do transplantation. There are two ways to accomplish this. One method is to induce cells into induced DA neurons (iDAN) directly or to induce cells into induced pluripotent stem cells and ultimately into iDAN in vitro. Another option
Xiaozhuo Li, Kevin Fang, Fengping Wang
wiley   +1 more source

Neuroprotective effect of normal and modified mesenchymal stem cell‐derived exosomes by mitigating Alzheimer's‐related oxidative and inflammatory damage via Nrf2/HO‐1 in SH‐SY5Y cells

Ibrain, EarlyView.
Exosome therapy shows promise in Alzheimer's disease. This study compared normal and modified exosomes from AD brain extract‐treated MSCs in STZ‐induced SH‐SY5Y cells. Exosomes improved neuronal viability, reduced oxidative stress and inflammation, and activated Nrf2/HO‐1 signaling.
Rishika Dhapola, Prajjwal Sharma, Sneha Kumari, Balachandar Vellingiri, Dibbanti HariKrishnaReddy   +4 more
wiley   +1 more source

Serotonin neuromicrobiology: Psychobiotic modulation of the gut–brain axis for mental health

Ibrain, EarlyView.
An overview of Psychobiotics and Tryptophan metabolism: A serotonin‐kynurenine crosstalk shaping the Gut‐Brain axis. IDO1, Indoleamine 2,3‐dioxygenase 1; 5‐HT3, 5‐hydroxytryptamine type 3; IFN‐γ, Interferon‐gamma; TNF‐α, Tumor necrosis factor‐alpha; IL‐1β, Interleukin‐1 beta; IL‐6, Interleukin 6; Trp, Tryptophan; 5‐HT, 5‐hydroxy‐tryptamine; 5‐HTP, 5 ...
Nidhi Mandloi, Aarzoo, Chakkaravarthi Saravanan, Heera Ram, Bhim Pratap Singh   +4 more
wiley   +1 more source

Human biomarker navigator

iMeta, EarlyView.
The Human Biomarker Navigator integrates the disease continuum, biomarker dynamics, cross‐organ biomarker networks, biomarker classification, and technology‐driven paradigms. It maps how biomarkers link multi‐system physiology and pathology across the nervous, respiratory, endocrine, circulatory, immune, digestive, urinary, reproductive, and ...
Meng‐Yao Li, Qian Zhang, Zijie Wang, Zeping Gui, Jing Liu, Jingda Li, Maojun Jiang, Zukang Chang, Qingqing Han, Bendong Yang, Tariq Saeed, Jun Li, Jinghan Jia, Chenghu Song, Tong Shao, Tianhuan Peng, Xueying Zhang, Pingping Guo, Jun Luo, Gangao Yang, Yuan Wan, Gokhan Zengin, Quan Yuan, Lingru Li, Xiaohui Fan, Yang Luo, Lvyun Zhu, Yanfei Zheng, Wenjun Mao, Wenlong Sun   +29 more
wiley   +1 more source

Engineered 3D cultured human nasal mucosa mesenchymal stem cell derived sEVs for targeted brain‐derived neurotrophic factor delivery to enhance neurogenesis and attenuate brain damage

Interdisciplinary Medicine, EarlyView.
This study successfully developed and evaluated BDNF@RVG‐sEVs, a novel brain‐targeted nanomedicine based on hnmMSC‐derived sEVs, designed to overcome the BBB and enhance neurorestoration. By integrating RVG for enhanced brain targeting and encapsulating BDNF for potent neurorepair, our system address the key limitations of the conventional sEVs and ...
Xueting Wang, Junge Chen, Jiao Xia, Weitong Yang, Teng Ma, Tianzi Shan, Weifeng He, Gaoman Zhang, Zhuoran Xia, Weiwei Wang, Zhusheng Liu, Zhiqiang Yi, Piye Niu, Tian Chen   +13 more
wiley   +1 more source

Developmental and Behavioral Effects of Arsenobetaine in Zebrafish (Danio rerio)

Journal of Applied Toxicology, EarlyView.
ABSTRACT Arsenobetaine (AsB) is a prevalent organoarsenical in aquatic environments and is generally regarded as nontoxic. Despite its widespread occurrence, the developmental and neurobehavioral toxicity of AsB has not been systematically investigated.
Sravan Kumar Putnala, Prerita Sharma, Prannav Jain, Samira Leila Baldin, Owen Luo, A. K. M. Munzurul Hasan, Md Helal Uddin, Mahesh Rachamalla, Som Niyogi   +8 more
wiley   +1 more source

Pulsed Electromagnetic Fields: A Novel Attractive Therapeutic Opportunity for Neuroprotection After Acute Cerebral Ischemia

Neuromodulation: Technology at the Neural Interface, EarlyView., 2021
Abstract Objectives Acute cerebral ischemia is characterized by several pathological processes evolving during time, which contribute to the final tissue damage. Secondary processes, such as prolonged inflammatory response, impaired mitochondrial function and oxidative stress, are responsible for the progression of brain injury to the peri‐infarct area,
Fioravante Capone, Simona Salati, Fabrizio Vincenzi, Micaela Liberti, Giorgio Aicardi, Francesca Apollonio, Katia Varani, Ruggero Cadossi, Vincenzo Di Lazzaro   +8 more
wiley   +1 more source

The effects of royal jelly on human health: A narrative review of clinical studies

JSFA reports, EarlyView.
Abstract Royal jelly (RJ) is a natural bioactive substance with documented effects on human health. This narrative review synthesizes evidence from clinical and clinically relevant experimental studies evaluating the therapeutic potential of RJ.
Georgios Goras, Andreas Thrasyvoulou, Evanthia Tsilimpokou   +2 more
wiley   +1 more source

A Randomized, Sham‐Controlled Trial of Repetitive Transcranial Magnetic Stimulation Targeting M1 and S2 in Central Poststroke Pain: A Pilot Trial

Neuromodulation: Technology at the Neural Interface, EarlyView., 2021
Abstract Objectives Central poststroke pain (CPSP), a neuropathic pain condition, is difficult to treat. Repetitive transcranial magnetic stimulation (rTMS) targeted to the primary motor cortex (M1) can alleviate the condition, but not all patients respond. We aimed to assess a promising alternative rTMS target, the secondary somatosensory cortex (S2),
Juhani Ojala, Jukka Vanhanen, Hanna Harno, Pantelis Lioumis, Selja Vaalto, Mari A. Kaunisto, Jukka Putaala, Marko Kangasniemi, Erika Kirveskari, Jyrki P. Mäkelä, Eija Kalso   +10 more
wiley   +1 more source